

Amendments to the Claims:

1. (Original) A polymorphic form of 9-nitrocamptothecin, the polymorph being characterizable as having, by differential scanning calorimetry, no observable endotherm and an exotherm at between 273.6 and 275.6 °C, and a solution NMR spectrum with multiplets at 1.7 and 3.7 ppm shifts.
2. (Original) A polymorphic form of 9-nitrocamptothecin according to claim 1, the polymorph being further characterizable as having an exotherm by differential scanning calorimetry at between 274.1 and 275.1 °C.
3. (Original) A polymorphic form of 9-nitrocamptothecin according to claim 1, the polymorph being further characterizable as having an exotherm by differential scanning calorimetry at between 274.4 and 274.8 °C.
4. (Original) A polymorphic form of 9-nitrocamptothecin according to claim 1, the polymorph being further characterizable as having an exotherm by differential scanning calorimetry at between 274.5 and 274.7 °C.
5. (Original) A polymorphic form of 9-nitrocamptothecin according to claim 1, wherein the polymorph is obtained by grinding.
6. (Original) A polymorphic form of 9-nitrocamptothecin, the polymorph being characterizable as having an X-ray powder diffraction pattern with diffraction lines at 2θ values 6.7, 12.5, 14.0 and 23.9 for Cu $K\alpha$ radiation of wavelength 1.5406 Angstrom.
7. (Original) A polymorphic form of 9-nitrocamptothecin, the polymorph being characterizable as having an X-ray powder diffraction pattern with diffraction lines at 2θ values 6.7, 12.5, 14.0 and 23.9 for Cu $K\alpha$ radiation of wavelength 1.5406 Angstrom.

8. (Original) A polymorphic form of 9-nitrocamptothecin, the polymorph being characterizable as having, for Cu $K\alpha$ radiation of wavelength 1.5406 Angstrom, an X-ray powder diffraction pattern with diffraction lines at 2θ values 6.7, 12.5, 14.0 and 23.9.
9. (Currently Amended) A polymorphic form of 9-nitrocamptothecin ~~in a form~~ crystallized from tetrahydrofuran.
10. (Original) A polymorphic form of 9-nitrocamptothecin according to claim 10, the polymorph being characterizable as having, by differential scanning calorimetry, no observable endotherm and an exotherm at between 273.6 and 275.6 °C, and a solution NMR spectrum with multiplets at 1.7 and 3.7 ppm shifts.
11. (Original) A polymorphic form of 9-nitrocamptothecin according to claim 10, the polymorph being characterizable as having an X-ray powder diffraction pattern with diffraction lines at 2θ values 6.7, 12.5, 14.0 and 23.9 for Cu $K\alpha$ radiation of wavelength 1.5406 Angstrom.
12. (Original) A polymorphic form of 9-nitrocamptothecin according to claim 10, the polymorph being characterizable as having an X-ray powder diffraction pattern with diffraction lines at 2θ values 6.7, 12.5, 14.0 and 23.9 for Cu $K\alpha$ radiation of wavelength 1.5406 Angstrom.
13. (Original) A polymorphic form of 9-nitrocamptothecin according to claim 10, the polymorph being characterizable as having, for Cu $K\alpha$ radiation of wavelength 1.5406 Angstrom, an X-ray powder diffraction pattern with diffraction lines at 2θ values 6.7, 12.5, 14.0 and 23.9.
14. (Original) A pharmaceutical composition comprising:
a pharmaceutical carrier; and
a polymorphic form of 9-nitrocamptothecin, the polymorph being characterizable as having, by differential scanning calorimetry, no observable endotherm and an exotherm at between 273.6 and 275.6 °C, and a solution NMR spectrum with multiplets at 1.7 and 3.7 ppm shifts.

15. (Original) A pharmaceutical composition according to claim 14, the polymorph being further characterizable as having an exotherm by differential scanning calorimetry at between 274.1 and 275.1 °C.
16. (Original) A pharmaceutical composition according to claim 14, the polymorph being further characterizable as having an exotherm by differential scanning calorimetry at between 274.4 and 274.8 °C.
17. (Original) A pharmaceutical composition according to claim 14, the polymorph being further characterizable as having an exotherm by differential scanning calorimetry at between 274.5 and 274.7 °C.
18. (Original) A pharmaceutical composition comprising:
a pharmaceutical carrier; and
a polymorphic form of 9-nitrocamptothecin, the polymorph being characterizable as having an X-ray powder diffraction pattern with diffraction lines at 2θ values 6.7, 12.5, 14.0 and 23.9 for Cu $K\alpha$ radiation of wavelength 1.5406 Angstrom.
19. (Original) A pharmaceutical composition comprising:
a pharmaceutical carrier; and
a polymorphic form of 9-nitrocamptothecin, the polymorph being characterizable as having an X-ray powder diffraction pattern with diffraction lines at 2θ values 6.7, 12.5, 14.0 and 23.9 for Cu $K\alpha$ radiation of wavelength 1.5406 Angstrom.
20. (Original) A pharmaceutical composition comprising:
a pharmaceutical carrier; and
a polymorphic form of 9-nitrocamptothecin, the polymorph being characterizable as having, for Cu $K\alpha$ radiation of wavelength 1.5406 Angstrom, an X-ray powder diffraction pattern with diffraction lines at 2θ values 6.7, 12.5, 14.0 and 23.9.

21. (Original) A pharmaceutical composition comprising:
a pharmaceutical carrier; and
a polymorphic 9-nitrocamptothecin in a form crystallized from tetrahydrofuran.
22. (Original) A pharmaceutical composition according to claim 21, the polymorph being characterizable as having, by differential scanning calorimetry, no observable endotherm and an exotherm at between 273.6 and 275.6 °C, and a solution NMR spectrum with multiplets at 1.7 and 3.7 ppm shifts.
23. (Original) A pharmaceutical composition according to claim 21, the polymorph being characterizable as having an X-ray powder diffraction pattern with diffraction lines at $^{\circ}2\theta$ values 6.7, 12.5, 14.0 and 23.9 for Cu $K\alpha$ radiation of wavelength 1.5406 Angstrom.
24. (Original) A pharmaceutical composition according to claim 21, the polymorph being characterizable as having an X-ray powder diffraction pattern with diffraction lines at $^{\circ}2\theta$ values 6.7, 12.5, 14.0 and 23.9 for Cu $K\alpha$ radiation of wavelength 1.5406 Angstrom.
25. (Original) A pharmaceutical composition according to claim 21, the polymorph being characterizable as having, for Cu $K\alpha$ radiation of wavelength 1.5406 Angstrom, an X-ray powder diffraction pattern with diffraction lines at $^{\circ}2\theta$ values 6.7, 12.5, 14.0 and 23.9.
26. (Original) A method of preparing a polymorphic form of 9-nitrocamptothecin, the method comprising:
crystallizing 9-nitrocamptothecin from tetrahydrofuran.
27. (Original) A method according to claim 26, the polymorph being characterizable as having, by differential scanning calorimetry, no observable endotherm and an exotherm at between 273.6 and 275.6 °C, and a solution NMR spectrum with multiplets at 1.7 and 3.7 ppm shifts.

28. (Original) A method according to claim 26, the polymorph being characterizable as having an X-ray powder diffraction pattern with diffraction lines at $^{\circ}2\theta$ values 6.7, 12.5, 14.0 and 23.9 for Cu $K\alpha$ radiation of wavelength 1.5406 Angstrom.

29. (Original) A method according to claim 26, the polymorph being characterizable as having an X-ray powder diffraction pattern with diffraction lines at $^{\circ}2\theta$ values 6.7, 12.5, 14.0 and 23.9 for Cu $K\alpha$ radiation of wavelength 1.5406 Angstrom.

30. (Original) A method according to claim 26, the polymorph being characterizable as having, for Cu $K\alpha$ radiation of wavelength 1.5406 Angstrom, an X-ray powder diffraction pattern with diffraction lines at $^{\circ}2\theta$ values 6.7, 12.5, 14.0 and 23.9.